Clover Health Investments (CLOV) to Release Quarterly Earnings on Tuesday

Key Points

• Clover Health Investments will announce its Q2 2025 earnings on August 5th, with analysts expecting earnings of $0.03 per share and revenue of $468.30 million.
• In its last quarterly report, Clover Health reported $0.05 earnings per share, exceeding estimates but had a negative return on equity of 7.42% and a negative net margin of 1.69%.
• CEO Conrad Wai sold 91,197 shares recently, representing a 6.10% decrease in his position, while insiders collectively own 24.07% of the company's stock.

Clover Health Investments (NASDAQ:CLOV - Get Free Report) will likely be announcing its Q2 2025 earnings results after the market closes on Tuesday, August 5th. Analysts expect the company to announce earnings of $0.03 per share and revenue of $468.30 million for the quarter.

Clover Health Investments (NASDAQ:CLOV - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.12. Clover Health Investments had a negative return on equity of 7.42% and a negative net margin of 1.69%. The company had revenue of $462.33 million during the quarter, compared to analyst estimates of $466.93 million. On average, analysts expect Clover Health Investments to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Clover Health Investments Stock Performance

Shares of CLOV opened at $3.00 on Tuesday. The business has a 50-day moving average of $3.01 and a 200 day moving average of $3.56. Clover Health Investments has a fifty-two week low of $1.50 and a fifty-two week high of $4.87. The firm has a market cap of $1.53 billion, a P/E ratio of -60.00 and a beta of 1.86.

Insiders Place Their Bets

In related news, CEO Conrad Wai sold 91,197 shares of Clover Health Investments stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $3.32, for a total value of $302,774.04. Following the completion of the sale, the chief executive officer owned 1,403,701 shares of the company's stock, valued at approximately $4,660,287.32. This trade represents a 6.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 24.07% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CLOV. Integrated Wealth Concepts LLC purchased a new position in Clover Health Investments during the 1st quarter valued at about $37,000. AQR Capital Management LLC purchased a new position in Clover Health Investments during the 1st quarter valued at about $49,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Clover Health Investments by 3.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 855,264 shares of the company's stock valued at $3,070,000 after buying an additional 24,807 shares in the last quarter. Hedge funds and other institutional investors own 19.77% of the company's stock.

Clover Health Investments Company Profile

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.